Farnesyltransferase inhibition overcomes the adaptive resistance to osimertinib in EGFR-mutant NSCLC

Sarah Figarol (1) , Célia Delahaye (1) , Rémi Gence , Raghda Asslan , Sandra Pagano , Claudine Tardy , Jacques Colinge , Jean-Philippe Villemin , Antonio Maraver , Irene Ferrer , Luis Paz-Ares , Isabelle Lajoie-Mazenc , Estelle Clermont , Anne Casanova , Anne Pradines , Julien Mazières , Olivier Calvayrac (1) , Gilles Favre (1)

1 CRCT - Centre de Recherches en Cancérologie de Toulouse

Drug-tolerant "dormant" cells (DTC) have emerged as one of the major non-genetic mechanisms driving resistance to targeted therapy in lung cancer, although the sequence of events leading to entry and exit from dormancy remain poorly described. Here, we performed real-time monitoring of the cell cycle dynamics during the adaptive response to Epidermal Growth Factor Receptor tyrosine kinase inhibitors (EGFR-TKi) in a panel of EGFR-mutated lung cancer cell lines. We identified a rare population of S/G2 cycling cells (referred to as early escapers) that emerged in the first

Domaines: Cancer

Sarah Figarol, Célia Delahaye, Rémi Gence, Raghda Asslan, Sandra Pagano, et al.. Farnesyltransferase inhibition overcomes the adaptive resistance to osimertinib in EGFR-mutant NSCLC. 2022. ⟨hal-03843955⟩